Zacks Investment Research on MSN
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
CRISPR Therapeutics CRSP reported a third-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of ...
For the first time, researchers at the Technical University of Munich (TUM) have succeeded in using nanorobots to stimulate ...
Researchers created a nanoparticle-stem cell technology that greatly enhances 3D bone regeneration, advancing treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback